Patent details

EP2984097 Title: HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV

Basic Information

Publication number:
EP2984097
PCT Application Number:
US2014034018
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP147229553
PCT Publication Number:
WO2014169278
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV
French Title of Invention:
DÉRIVÉ DE NUCLÉOSIDE D'ACTIVITÉ ÉLEVÉE POUR LE TRAITEMENT DU VHC
German Title of Invention:
HOCHAKTIVE NUKLEOSIDDERIVATE ZUR BEHANDLUNG VON HCV
SPC Number:

Dates

Filing date:
14/04/2014
Grant date:
29/03/2017
EP Publication Date:
17/02/2016
PCT Publication Date:
16/10/2014
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
29/03/2017
EP B1 Publication Date:
29/03/2017
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
14/04/2017
Expiration date:
14/04/2034
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
29/03/2017
 
 

Name:
Achillion Pharmaceuticals, Inc.
Address:
300 George Street, New Haven, CT 06511, United States (US)

Inventor

1

Name:
PHADKE, Avinash
Address:
United States (US)

2

Name:
DESHPANDE, Milind
Address:
United States (US)

3

Name:
HASHIMOTO, Akihiro
Address:
United States (US)

4

Name:
WILES, Jason Allan
Address:
United States (US)

Priority

Priority Number:
201361811464 P
Priority Date:
12/04/2013
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/7072; A61P 31/14; C07B 59/00; C07H 19/067;

Publication

European Patent Bulletin

Issue number:
201713
Publication date:
29/03/2017
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
13/09/2017 Outgoing Correspondence 1